US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Research & Development: market research reports

The term research and development (R&D) refers to work that is done in order to better understand the nature, function or understanding of a topic or product in order to gain knowledge and find new applications for existing products or to develop new and innovative products. This is usually performed by corporations, government agencies, and research or academic institutions.

New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.

Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.

RSS Feeds

Research & Development market research reports and industry analysis

< prev 1    3  4  5  6  7  8  9  10  
PHARMACEUTICAL MARKET INDIA 2014-2020 : Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines
8/1/2014 | published by: Kelly Scientific Publications
... Biosimilars, Generics & Vaccines” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle ...  |  read more...
USD 2,000
Global Parkinson's Disease Market : 2014-2018
7/23/2014 | published by: TechNavio - Infiniti Research Ltd.
... GlaxoSmithKline plc, Novartis AG and Teva Pharmaceutical Industries Ltd. Other prominent vendors in this market are: Abbvie Inc., Akorn Inc., Astellas Pharma Inc., Desitin Arzneimittel GmbH, Endo International plc, F. Hoffmann-La Roche Ltd., H. Lundbeck ...  |  read more...
USD 2,500
Proteins in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 667 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 190 drugs. Proteins In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,746
RANKL Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... and plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C ...  |  read more...
USD 6,746
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 28 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ...  |  read more...
USD 4,496
Leukemia Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 127 drugs. Leukemia Drug Pipeline Update lists all drugs and gives ...  |  read more...
USD 6,746
The Latest Sales Figures in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... global pharmacuetical companies to progressive biotech companies. The analysis leverages the power of BioSeeker's 1stOncology intelligence which combines company disclosed product sales and detailed drug development information. The results is not only a unique insight ...  |  read more...
USD 4,478
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... in 1411 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 227 drugs. Tgf-Beta Receptor Signaling Pathway In Oncology ...  |  read more...
USD 6,746
Hematological Cancers Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 765 hematological cancer drugs in 1629 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 230 drugs. Hematological Cancers ...  |  read more...
USD 8,996
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 215 companies plus ...  |  read more...
USD 6,746
Orphan Drugs in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to ...  |  read more...
USD 6,746
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, ...  |  read more...
USD 6,746
Lung Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe ...  |  read more...
USD 6,746
Immunotherapy in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... of antibodies, vaccines, and immunostimulators in oncology drug development into one source. There are today 596 companies plus partners developing 1094 cancer immunotherapy drugs in 2802 developmental projects in cancer. In addition, there are 19 ...  |  read more...
USD 11,025
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... drugs in 1307 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 152 drugs. Il-2 Signaling Pathway In Oncology ...  |  read more...
USD 6,746
IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 724 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 81 drugs. Il-4 Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
USD 6,746
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 667 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 68 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
USD 6,746
Cytokine Therapy in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 8 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
USD 4,496
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 312 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,746
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 223 drugs. Androgen Receptor Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
USD 6,746
Apoptosis in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... cancer cells. There are today 347 companies plus partners developing 431 apoptotic drugs in 1996 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the ...  |  read more...
USD 6,746
Biologicals in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... developing 1686 biological drugs in 3815 developmental projects in cancer. In addition, there are 28 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 932 drugs. Biologicals In ...  |  read more...
USD 11,246
ID Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... other family members inhibiting their DNA binding capacity. This family of proteins is comprised of IDs 1, 2, 3 and 4. There are today 94 companies plus partners developing 96 ID pathway targeting drugs in ...  |  read more...
USD 2,246
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 27 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 2,246
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... in 2048 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 257 drugs. Tnf-Alpha Signaling Pathway In Oncology Drug ...  |  read more...
USD 6,746
< prev 1    3  4  5  6  7  8  9  10